Lymphocyte-to-monocyte ratio associated with survival in melanoma patients treated with pembrolizumab (Keytruda)

Learning how well we are responding to a melanoma therapy or even predicting that response with a simple blood test would be sooooooooooooo AWESOME!!!!  Researchers have been looking at various lab values in that regard.  Here are some of the articles I've posted on the topic:

2015: Lab values that may predict response to Ipi/Yervoy????
2016: Biomarkers - blood components, circulating tumor cells AND of the tumor itself
Blood markers associated with clinical outcome of melanoma treated with ipi
2017: Eosinophilia - biomarker for prognosis in melanoma and importance in immunotherapy response

Now, there's this:

Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients. Failing, Yan, Porrata, Markovic. Melanoma Res. 2017 Oct 9.

The peripheral blood lymphocyte-to-monocyte ratio (LMR) has been associated with prognosis in many malignancies including metastatic melanoma. However, it has not been studied in patients treated with immune checkpoint inhibitors. In this study, we analyzed the baseline LMR with progression-free survival (PFS) and overall survival (OS) in metastatic melanoma patients treated with pembrolizumab. A total of 133 patients with metastatic melanoma treated with pembrolizumab were included in this retrospective study. LMR was calculated from pretherapy peripheral blood counts and the optimal cutoff value was determined by a receiver operator characteristic curve. PFS and OS were evaluated using the Kaplan-Meier method and multivariate Cox proportional hazard modeling. Patients with an LMR of at least 1.7 showed improved PFS and OS. The baseline LMR is associated with PFS and OS in metastatic melanoma patients treated with pembrolizumab, and could represent a convenient and cost-effective prognostic biomarker. Validation of these findings in an independent cohort is needed.

Every bit of intel helps!!  Hang tough, ratties!! - c